Class Actions Filed for Investors in AstraZeneca, Applied Therapeutics, Kyverna Therapeutics, Five9

AstraZeneca PLC is facing a class action securities lawsuit for alleged fraud involving insurance practices in China, which reportedly resulted in the detention of its China President and understated legal risks. Investors who purchased AstraZeneca securities between February 23, 2022, and December 17, 2024, can join the case, with a deadline to request lead plaintiff status set for February 21, 2025. The lawsuit claims that misleading statements about the company's operations and prospects were made, which could harm its business activities in China. Meanwhile, other class action lawsuits have been initiated against Applied Therapeutics and Kyverna Therapeutics for similar allegations of securities fraud, with specific timelines for affected investors to join. Investors in Five9, Inc. are also being notified of a pending lawsuit due to alleged inaccuracies regarding the company's business performance during a challenging economic period. Legal firms are encouraging impacted investors to reach out for possible compensation without upfront costs.